CD44 and EGFR Dual-Targeted Antibody-Recruiting Complex Based on Hyaluronic Acid Grafted with β-Cyclodextrin and Multivalent Rhamnose for Cancer Immunotherapy

Abstract

A new generation of multivalent antibody-recruiting molecules (ARMs) with dual-targeting tumor-binding termini (TBT), including hyaluronic acid targeting CD44 and nanobody 7D12 or peptide GE11 targeting EGFR, was constructed for cancer immunotherapy. The 7D12 or GE11 were assembled onto β-cyclodextrin-grafted hyaluronic acid (HACD) with multivalent rhamnose via host-guest interaction to form macromolecule complexes. The immunological studies proved that these complexes had dual-targetability on CD44 and EGFR and the rhamnose on HACD could recruit anti-Rha antibodies to mediate cytotoxicity against the targeted tumor cells. This bispecific ARM strategy provides a platform for cancer immunotherapy.